본 보고서는 세계 주요 바이오 제약사들이 체결한 단클론항체 관련 계약에 대한 종합적인 이해와 정보 접근성을 제공합니다.
본 보고서에서는 기업들이 어떻게, 그리고 왜 단클론항체 관련 계약을 체결하는지에 대한 상세한 이해와 분석을 제공합니다. 이러한 계약은 일반적으로 복합적인 구성을 가지고 있으며, 공동 연구개발에서 시작하여 그 결과물의 상업화로 발전하는 경우가 많습니다.
수록 대상에는 공동 연구, 개발, 라이선스 계약을 포함한 다양한 유형의 제휴 계약이 포함됩니다.
본 보고서에는 2019년 이후 발표된 670건의 단클론항체 관련 계약 목록이 수록되어 있으며, 가능한 한 계약 금액 등 재무 조건도 포함되어 있습니다. 또한, 각 계약의 온라인 기록에 대한 링크도 함께 수록되어 있어 실제 공개된 계약의 내용을 확인할 수 있습니다. 또한, 가능한 경우 기업 및 파트너사가 미국 증권거래위원회(SEC)에 제출한 계약 문서도 기록에 포함되어 있습니다.
주요 장점:
- 2019년 이후 계약 동향 파악
- 단클론항체 관련 공동 연구 및 라이선스 계약 열람하기
- 벤치마크 분석 : 거래의 시장 가치 파악
- 재무 조건 세부 사항 : 일시금, 마일스톤, 로열티
- 업체명(A-Z), 계약 유형, 치료 분야별 계약 디렉토리
- 금액 기준 주요 계약 사례
- 가장 활발한 딜 메이커
- 각 계약의 대상 자산 및 계약 조건 명시
- 계약 문서에 액세스 : 계약 구조에 대한 심층적인 인사이트
- 실사 : 제안 중인 계약 조건이 파트너사에게 적합한지 여부를 평가합니다.
- 수백 시간 분량의 조사 시간 절약 가능
계약서 분석을 통해 다음과 같은 사항에 대한 실사를 할 수 있습니다:
- 정확히 어떤 권리가 부여 또는 옵션으로 주어지는가?
- 계약에 따라 파트너사에게 실제로 부여되는 혜택은 무엇인가?
- 어떤 독점권이 주어지는가?
- 계약금 지급 구조는 어떻게 되는가?
- 매출과 결제는 어떻게 감사하는가?
- 계약기간(유효기간)은 어떻게 되는가?
- 계약의 주요 조항은 어떻게 정의되어 있는가?
- 지적재산권(IPR)은 어떻게 취급되며, 누가 소유하고 있는가?
- 상업화 책임은 누가 져야 하는가?
- 개발, 공급, 제조의 책임은 누구에게 있는가?
- 비밀유지 및 성과 공개는 어떻게 관리되는가?
- 분쟁은 어떻게 해결해야 하는가?
- 어떤 조건에서 계약을 해지할 수 있는가?
- 기업의 소유권이 변경된 경우, 계약은 어떻게 되는가?
- 서브 라이선스 및 하도급에 관한 조항은 어떻게 합의되어 있는가?
- 회사 측에서 반드시 포함시키는 '모범 조항'은 무엇인가?
- 계약 상대방이나 계약 유형에 따라 달라지는 '모범규준 조항'은 무엇인가?
- 계약법상 회사가 준거법으로 요구하는 법역(관할권)은 어디인가?
목차
주요 요약
제1장 소개
제2장 단클론항체 거래 동향
- 연도별 단클론항체 계약 건수
- 가장 활발한 계약 체결 기업
- 단클론항체 계약 : 계약 유형별
- 단클론항체 계약 : 치료 분야별
- 단클론항체 계약 : 업계별
- 단클론항체 거래의 거래 조건
제3장 주요 단클론항체 계약
제4장 가장 활발한 단클론항체 계약 체결 기업
- 가장 활발한 단클론항체 계약 체결 기업
- 가장 활발한 단클론항체 계약 체결 기업 개요
제5장 단클론항체 계약 거래 디렉토리
제6장 단클론항체 계약 : 기술 유형별
- 계약 디렉토리
- 계약 디렉토리 기업별(A-Z)
- 계약 디렉토리 계약 유형별
- 계약 디렉토리 치료 분야별
- 계약 유형의 정의
- Biopharma Research Ltd에 대해
- 현재 제휴
- 현재 계약
- Current Partnering의 최근 보고서 제목
ksm
Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of monoclonal antibody deals from 2019 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 670 monoclonal antibody deals announced since 2019 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2019.
Chapter 3 provides an overview of the leading monoclonal antibody deals since 2019. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific monoclonal antibody technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2019.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse monoclonal antibody collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
- Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.
Monoclonal Antibody Collaboration and Licensing Deals includes:
- Trends in monoclonal antibody dealmaking in the biopharma industry
- Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
- The leading monoclonal antibody deals by value
- Most active monoclonal antibody licensing dealmakers
- Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in monoclonal antibody dealmaking
- 2.1. Introduction
- 2.2. Monoclonal antibody deals over the years
- 2.3. Most active monoclonal antibody dealmakers
- 2.4. Monoclonal antibody deals by deal type
- 2.5. Monoclonal antibody deals by therapy area
- 2.6. Monoclonal antibody deals by industry sector
- 2.7. Deal terms for monoclonal antibody deals
- 2.7.1 Monoclonal antibody deals headline values
- 2.7.2 Monoclonal antibody deal upfront payments
- 2.7.3 Monoclonal antibody deal milestone payments
- 2.7.4 Monoclonal antibody royalty rates
Chapter 3 - Leading monoclonal antibody deals
- 3.1. Introduction
- 3.2. Top monoclonal antibody deals by value
Chapter 4 - Most active monoclonal antibody dealmakers
- 4.1. Introduction
- 4.2. Most active monoclonal antibody dealmakers
- 4.3. Most active monoclonal antibody deals company profiles
Chapter 5 - Monoclonal antibody contracts dealmaking directory
- 5.1. Introduction
- 5.2. Monoclonal antibody contracts dealmaking directory
Chapter 6 - Monoclonal antibody dealmaking by technology type
- Deal directory
- Deal directory - Monoclonal antibody deals by company A-Z
- Deal directory - Monoclonal antibody deals by deal type
- Deal directory - Monoclonal antibody deals by therapy area
- Deal type definitions
- About Biopharma Research Ltd
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
Table of figures
- Figure 1: Monoclonal antibody deals since 2019
- Figure 2: Active monoclonal antibody dealmaking activity - 2019 - 2025
- Figure 3: Monoclonal antibody deals by deal type since 2019
- Figure 4: Monoclonal antibody deals by therapy area since 2019
- Figure 5: Monoclonal antibody deals by industry sector since 2019
- Figure 6: Monoclonal antibody deals with a headline value
- Figure 7: Monoclonal antibody deals with an upfront value
- Figure 8: Monoclonal antibody deals with a milestone value
- Figure 9: Monoclonal antibody deals with a royalty rate value
- Figure 10: Top monoclonal antibody deals by value since 2019
- Figure 11: Most active monoclonal antibody dealmakers 2019 - 2025
- Figure 12: Monoclonal antibody deals by technology type since 2019
